Current trials
Explore our clinical trials that are currently open for recruitment. Our trials cover a range of disease areas and recruit patients from specific disease groups and populations.
DNDi-6899
A phase 1 (food effect and multiple ascending dose) trial. This study is evaluating the safety, tolerability and pharmacokinetics of a single dose and repeat doses of DNDi-6899 in healthy volunteers. This trial is being conducted in Liverpool, UK at the NIHR Liverpool clinical research facility, Liverpool University Hospitals Foundation Trust.
AGILE Clinical trial platform
AGILE is a seamless Phase I/II platform for the rapid evaluation of candidates for COVID-19 treatment. AGILE is a collaboration between the University of Liverpool, Liverpool University Hospitals NHS Foundation Trust, Liverpool School of Tropical Medicine and University of Cambridge. The collaboration also has partners in Sub-Saharan Africa – Desmond Tutu Health Foundation, South Africa, Ezintsha, South Africa and Infectious Diseases Institute, Uganda.
More information about the platform and the clinical trials can be found on the dedicated AGILE Clinical trial platform website.
The trial is registered on clinicaltrials.gov NCT04746183 and ISRCTN 27106947.
Differences in levels of heart fat in people living with HIV and the general population
This study is looking at the relationship between epicardial adipose tissue volume and cardiovascular risk in people living with HIV and the general population. This trial is being conducted in Liverpool, UK at the NIHR Liverpool clinical research facility, Liverpool University Hospitals Foundation Trust.
The trial is registered on ISRCTN 47550369.
DoraDO
DoraDO is a study exploring the pharmacokinetics, safety and efficacy of the HIV drug doravirine in pregnant women who are living with HIV. This trial is being conducted in Cape Town, South Africa at the Desmond Tutu Health Foundation.
The trial is registered on clinicaltrials.gov NCT05630638.
DoRIS
DoRIS is a study exploring the pharmacokinetics of the HIV drug dolutegravir when given with different doses of the TB drug rifampicin. This trial is being conducted in Cape Town, South Africa at the Desmond Tutu Health Foundation and in Kampala, Uganda at the Infectious Diseases Institute.
The trial is registered on clinicaltrials.gov NCT04166474.
DolPHIN-2
DolPHIN-2 is a multinational project aimed at reducing the rate of vertical transmission of HIV comprising of a clinical trial, qualitative research, pharmacoeconomic evaluation and infant safety follow-up.
The clinical trial is registered on clinicaltrials.gov NCT03249181.
Find out more about DolPHIN-2.